178 related articles for article (PubMed ID: 7678930)
1. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
Guess HA; Heyse JF; Gormley GJ
Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
[TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
3. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
[TBL] [Abstract][Full Text] [Related]
4. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
5. Effects of finasteride on prostate volume and prostate-specific antigen.
Chiu KY; Yong CR
J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071
[TBL] [Abstract][Full Text] [Related]
6. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
7. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
[TBL] [Abstract][Full Text] [Related]
8. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
9. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
[TBL] [Abstract][Full Text] [Related]
10. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
[TBL] [Abstract][Full Text] [Related]
11. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
12. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
13. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
14. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
Tammela TL; Kontturi MJ
J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
16. Finasteride: a 5 alpha-reductase inhibitor.
Steiner JF
Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.
Presti JC; Fair WR; Andriole G; Sogani PC; Seidmon EJ; Ferguson D; Ng J; Gormley GJ
J Urol; 1992 Oct; 148(4):1201-4. PubMed ID: 1383574
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
19. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
20. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
